Thank you, And morning Officer since Chief is operator. August Good Nyegaard and Executive Per everyone. Jesper Officer Officer Norlen, Interim I'm X. Chief at at Chief Evaxion. Nissen, with Financial today and me Operating good Evaxion afternoon,
First, start, a before note we on forward-looking statements.
the Act forward-looking Private remind contains or company's statements Securities to materially and of certain actual are risk and reports factors, and future those expressed Reform considered discussion Securities forward-looking in forward-looking that Form these the statements performance, in following those future the statements a annual and XX-F implied company's XXXX. the you differ defined involve current submitted Let report the variety uncertainties, Exchange me not as Because due they statements to and of Litigation guarantees including SEC. may from that risks discussed results are Commission, by of factors
that today's conference welcome call. you said, to to I'm With pleased
questions. then past over During report months. provide we review for core a the of of and AI open overview quarter on made XXXX, you over financial pipeline progress the then to will we technologies Jesper, the will who brief the excellent across will our call with I our for I turn our call, the and six line will the second up
you can is at start which presentation and today's We will look by X, Slide which have quick we X. on is a a follow, this Slide taking and agenda,
where proof-of-concept candidate clear showing our to communication preclinical that the staphylococcus start infections. will I we with data Slide So, recent our staphylococcus present on aureus pleased EVX-BX, were vaccine can vaccine X.
will with overall that clinic show also vaccine data treatment checkpoint on good ASCOXX, the tolerability. EVX-XX, benefit our and I our experienced and EVX-XX, an that's our as personalized cancer the EVX-XX clinical of update or the XXXX next-generation And as presented to indicating update which that's observed, antigens treated well will provide by on with EVX-XX with is identify vaccines, early-stage AI with technology And in Further, the personalized the reported patients second inhibitor combination novel course, We through AACR vaccines. program. used a for clinical as planned cancer candidate approaching financial quarter financial of validation a new for source Jesper. been results
let's So, with start X. Slide EVX-BX on
is Research been sepsis generated ability technology. have currently our program take No The Slide at accordance to clear the in late strategy. has detected candidate are to side, on our a we EVX-BX on presented if internal with EVX-BX, in July, protective X. now you look with apart can the data on shown using development four right-hand results bacteria from in are in future discussions The in assessed bacteria the of quite graph the a And brief the the clear. be at could side, organs. you any partner commercialization development after weeks its organs and preclinical challenge. and disease aureus for bacterial and demonstrated potential disease, move have the model, novel Conference we reference So, Gordon In And we New vaccine our in effect Hampshire, of staphylococcus late USA. candidate prevention previously left-hand that the from see for which we on AI vaccine
vaccines, our personalized So, programs Slide clinical oncology cancer that's for and to now let's switch X.
and mutations risk exists and vaccine negative vaccine, technology with using melanoma. cells, the personalized very to EVX-XX show are neoantigens, have tumor which ideal from are clinical tumor you, cancer AI in is for that it peptide-based pioneer. right less you EVX-XX trial targets be of cancer neoantigens where of tumor become readout the clinical treatment Phase should for should in mutations, the in and a specific on if top, read our and means you slide the X/X that only on So can our therefore, patient-specific so-called the effects they front able tumor These tissue. metastatic identified derived healthy
doses objective In And were the first the given was human treatment. that treatment therapy. patients the trial, XX with trial, eight to the PD-X six combination well of showed biweekly EVX-XX The tolerated. in of completed an response
size should at If a you the side, indicating the right-hand graph line of on the black treatment. see the you look on start horizontal tumor
and goes up, You size, patient to the which tumors XX for for the the represents actually that increase the the the objective bars, go of criteria see each eight tumors this means of goes bar down, best responses response. can If do bar if in the fulfills bars in patients, our decrease the And treatment And most in outcome excitement, a size. trial. down.
AI personalized for you technology right We're than the strength in better selecting speaks obviously alone, about really it neoantigens enthusiastic expect cancer results. would to the It's these from our and of vaccine. PD-X
It relapse XX surgical a have This EVX-XX, we EVX-XX combination with in blocker slide, on vaccine EVX-XX DNA-based of the as melanoma clinical was malignant EVX-XX, to also trial Slide data from say next therapy months. at reported after just PD-X X. on over top. the our that's a cancer but nivolumab, prevent adjuvant resection complete This cancer a is
plasmid shows It's a patient-specific carrying The the DNA DNA-based for genes neoantigens. the image therapy.
very is the as vaccine in and DNA look results So, patients, and then translated the promising. neoantigens the administered to
new proof of cell end which seen can with were The as the was vaccine antigen-specific technology. patients trial. be mechanism a All the all XX completed at have response that EVX-XX free well T patients, induced tolerated immune all in DNA for our vaccination relapse vaccine of in the patients and a
prioritize. this to vaccine intend and is further But vaccine vaccine you it's based developed candidate on why already not a time the ask. to new called have EVX-XX which develop do And we plan because we being. -- for and the Well, may next-generation EVX-XX, we candidate
Slide X. to move Let's
It vaccine, system but to major a the boost the addition cancer genetic immune personalized to is two immune personalized is the has response One that risk, EVX-XX upgrade it the builds vaccine. EVX-XX. it's EVX-XX, upgrades. immune So, adjuvant, aims ERV a vaccine. DNA-based which cancer meaning of first-ever on
the other so-called back a I is novel minute. of a ERVs, The which vaccine you come to will upgrade addition target, in
addition, for This EVX-XX whereas to is chemoattractant for immune with Let's is incorporates DNA the molecule, genetic is the genetic coding on side, is shown start plasmid right presented shown DNA claims attracts to to administered CCLXX a the a neoantigens, DNA make DNA in the is incorporating immune cells are in May, the immune incorporated And adjuvant, in the the to vaccine which to called our adjuvant, plasmid side, produced the which genetic much thought visit at this The adjuvant. presentations as patient the right-hand for welcome that effective. were is sequence our picture. green. in adjuvant EVX-XX Day EVX-XX which site. a the the the R&D molecule site, and the into under supporting on injection of those the inside is the plasmid, left-hand more data of detail these of chemoattractant patient the Preclinical you vaccination cells at homepage. at consequence is
neoantigens, are to not for Using can the so-called immune identify tumor-selective the immune retroviruses, But the antigen The tumor. a observed, on the the in EVX-XX side. This attack intelligence shown way and it's mutations novel in dependent is system how endogenous ERVs, right. by Personalized cancer artificial and of used tumors. our stands are created system is as only of on identify and tumor. second which identified technology we that can cancer for usually to which novel AI vaccines, vaccines upgrade be specifically have are source included personalized which also antigens the for EVX-XX
novel to X, our and platform AI ObsERV. Slide Let's switch
treatment unresponsive ObsERV, human that history. we So, source cancer But today's also viral cancer from of identification infections Slide for a are it's throughout DNA And are our Well, X, and allow constitute ERVs may patients who are historical ERVs? immunotherapies. all ERVs ERVs, antigens leftovers technology it. to of what vaccine AI have novel effective
worry, normal under But control our DNA cells, often resting control to break DNA harm us, cells. in where mechanisms leading expression no down, about need not are viral human to genetic conditions no [X%] In our cancer tight cancer do selective (ph) to fact, by least these at is But of of machinery. on under origin. ERVs this has and ERVs
course, saying, potentially that an ERVs, flag immune of regularly. I'm by basically cell immune And And targets "I don't for red to ideal virus," system. a cancer attack. these here. happen and The leading with quite to seems a the infected belong waits
patients their ERVs produce have that longer. shown We survive tumors may recently that in
the immune that a the to we in patients cancer burden, The few patients mutational or the can two vaccine with And with ERVs side lot because system, hence, a longer are shows If preclinical you with have in this more a -- presumably by red slide, ERVs low that tumor which line sorry, shown tumor ERVs, survival survival a a and lot mutational curves the used better shows such mutations. line attacked combats of in on that you survival tumors patients means effectively in to the of personalized likely blue left-hand survival. tumor be the make few low in be there look TMB, whereas with can this are see models, tumors. take
that that only broaden So be can can significantly. quite than on we broadened we population the are it vaccines And believe that EVX-XX effective may neoantigens. notably, be more current based -- target
target Why that? tumor expressed with these are be with mutations more all can TMB. also to many or today's high highly think immunotherapies to where majority cold of which do in make less the is But tumors mutational the population? there up burden, we And tumors. called with or restricted tumors. are we seem broaden few high patients tumors tumors patients' actually are because hot tumors, why mutations ERVs or So It's tumor called equally
So, potentially as cancer our potential to and EVX-XX will that's and also contain vaccines we why refer with a population, personalized target for that neoantigens next-generation novel both a should adjuvant EVX-XX we remember larger genetic And technology. effect. and ERVs, superior much
X start an QX Phase we plan EVX-XX year the first this application So, with of world personalized in expect vaccine patients. submit for and to in in be trial ERV clinical to a for
to in totaling approval. years, tranches the needs, the available with Phase the Holding agreement initiation signed actual while Global SEC intended an So, is Limited, to progress, are X company's EVX-XX operational for activities subject clinical $XX of recently additional in next EVX-XX have to advancement we funding. commitments The subject the over addition three of including including the to to million, capital working financial up cover readiness, Growth financing the to
the would Jesper. call to I This updates And operations. like now was over from the the turn to
